Denosumab in patients with osteogenesis imperfecta and a historical control study with alendronate

Denosumab in patients with osteogenesis imperfecta and a historical control study with alendronate

PurposeOptimal dosing of denosumab in osteogenesis imperfecta (OI) remains undefined. This prospective cohort study evaluated the 12-month efficacy and safety of denosumab in OI patients, with a historical control study with alendronate.Materials and methodsEight pediatric patients (1 mg/kg every 3...

Full description

Saved in:
Bibliographic Details
Main Authors: Yazhao Mei, Shiya Cai, Yunyi Jiang, Yuan Tian, Li Shen, Jiemei Gu, Chun Wang, Zhenlin Zhang, Hao Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Endocrinology
Subjects:
osteogenesis imperfecta
denosumab
alendronate
hypercalcemia
bone mineral density
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2025.1445093/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2025.1445093/full

Similar Items